LohseN, HansenAB, PedersenG, et al.Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med, 2007; 146:87–95.
2.
ObelN, OmlandLH, KronborgG, et al.Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: A population-based nationwide cohort study. PLoS One, 2011; 6:e22698.
3.
HahnJA, SametJH. Alcohol and HIV disease progression: Weighing the evidence. Curr HIV/AIDS Rep, 2010; 7:226–233.
4.
BaumMK, RafieC, LaiS, SalesS, PageJB, CampaA. Alcohol use accelerates HIV disease progression. AIDS Res Hum Retroviruses, 2010; 26:511–518.
5.
BaumMK, RafieC, LaiS, SalesS, PageB, CampaA. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr, 2009; 50:93–99.
6.
So-ArmahKA, TateJP, ChangC-CH, et al.Do biomarkers of inflammation, monocyte activation, and altered coagulation explain excess mortality between HIV infected and uninfected people?. J Acquir Immune Defic Syndr, 2016; 72:206–213.
7.
FusterD, ChengDM, QuinnEK, et al.Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems. AIDS, 2014; 28:1059–1064.
8.
CapeauJ. Premature aging and premature age-related comorbidities in HIV-infected patients: Facts and hypotheses. Clin Infect Dis, 2011; 53:1127–1129.
9.
GrebelyJ, DoreGJ. What is killing people with hepatitis C virus infection?. Semin Liver Dis, 2011; 31:331–339.
10.
FusterD, SanvisensA, BolaoF, RivasI, TorJ, MugaR. Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. World J Hepatol, 2016; 8:1295–1308.
11.
JoshiD, O'GradyJ, DieterichD, GazzardB, AgarwalK. Increasing burden of liver disease in patients with HIV infection. Lancet, 2011; 377:1198–1209.
12.
MaidaI, NunezM, RiosMJ, et al.Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr, 2006; 42:177–182.
GeboKA, HerlongHF, TorbensonMS, et al.Role of liver biopsy in management of chronic hepatitis C: A systematic review. Hepatology, 2002; 36(5Suppl 1):S161–S172.
15.
SanvisensA, MuñozA, BolaoF, et al.Do serum markers of liver fibrosis vary by HCV infection in patients with alcohol use disorder?. Drug Alcohol Depend, 2018; 188:180–186.
16.
SterlingRK, LissenE, ClumeckN, et al.Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology, 2006; 43:1317–1325.
17.
BarocasJA, So-ArmahK, ChengDM, et al.Zinc deficiency and advanced liver fibrosis among HIV and hepatitis C co-infected anti-retroviral naïve persons with alcohol use in Russia. Strnad P, ed. PLoS One, 2019; 14:e0218852.
18.
JusticeAC, FreibergMS, TracyR, et al.Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV?. Clin Infect Dis, 2012; 54:984–994.
19.
BambhaK, PierceC, CoxC, et al.Assessing mortality in women with hepatitis C virus and human immunodeficiency virus using indirect markers of fibrosis. AIDS, 2012; 26:599–607.
20.
So-ArmahKA, LimJK, Lo ReV, et al.FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients. Hepatology, 2017; 66:1286–1295.
21.
ZaniniG, Sales MartinaA, ShermanKE, et al.Sex differences, cocaine use, and liver fibrosis among African Americans in the Miami Adult Study on HIV (MASH) Cohort. J Women's Health, 2020; 29:1176–1183.
22.
ValenteMJ, CarvalhoF, BastosMd, de PinhoPG, CarvalhoM. Contribution of oxidative metabolism to cocaine-induced liver and kidney damage. Curr Med Chem, 2012; 19:5601–5606.
23.
Dominguez-RodriguezA, Abreu-GonzalezP, Enjuanes-GrauC, Blanco-PalaciosG, Angeles Perez-CarrilloM de los, Burillo-PutzeG. Oxidative stress and inflammatory markers in cocaine users with acute coronary syndrome. Med Clin (Barc). 2010; 134:152–155.
24.
AraosP, PedrazM, SerranoA, et al.Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatient treatment: Influence of cocaine symptom severity and psychiatric co-morbidity. Addict Biol, 2015; 20:756–772.
25.
ArmahKA, McGinnisK, BakerJ, et al.HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis, 2012; 55:126–136.
26.
WalleyAY, PalmisanoJ, Sorensen-AlawadA, et al.Engagement and substance dependence in a primary care-based addiction treatment program for people infected with HIV and people at high-risk for HIV infection. J Subst Abuse Treat, 2015; 59:59–66.
